

Woonyoung Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10886136/publications.pdf>

Version: 2024-02-01

56
papers

7,530
citations

186265

28
h-index

189892

50
g-index

57
all docs

57
docs citations

57
times ranked

8494
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2021, 79, 364-371.	1.9	41
2	Editorial: Recent Advances in Diagnosis and Management of Urothelial Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656974.	2.8	0
3	Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. <i>Urology</i> , 2021, 156, 104-109.	1.0	2
4	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 548-557.	0.4	9
5	Role of immunotherapy in localized muscle invasive urothelial cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211045858.	3.2	4
6	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	1.9	741
7	Adaptive Immune Resistance to Intravesical BCG in Non-muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.	7.0	98
8	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>iScience</i> , 2020, 23, 101201.	4.1	18
9	The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. <i>Clinical Cancer Research</i> , 2020, 26, 4018-4030.	7.0	44
10	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. <i>Scientific Reports</i> , 2020, 10, 9743.	3.3	83
11	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 811-821.	3.4	4
12	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434-438. <i>European Urology</i> , 2020, 77, 436-438.	1.9	1
13	Update on bladder cancer molecular subtypes. <i>Translational Andrology and Urology</i> , 2020, 9, 2881-2889.	1.4	28
14	Tumor heterogeneity in muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2866-2880.	1.4	11
15	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. <i>Cell Reports</i> , 2019, 26, 2241-2256.e4.	6.4	31
16	ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers. <i>European Urology</i> , 2019, 75, 240-241.	1.9	2
17	Subtyping Bladder Cancers: Biology vs Bioinformatics. <i>Journal of the National Cancer Institute</i> , 2018, 110, 439-440.	6.3	4
18	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2018, , 369-382.		0

#	ARTICLE	IF	CITATIONS
19	Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>Eur Urol</i> 2017;72:354-65. <i>European Urology</i> , 2018, 73, e104-e105.	1.9	1
20	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. <i>European Urology Oncology</i> , 2018, 1, 54-60.	5.4	26
21	Molecular Subtypes of Bladder Cancer. <i>Current Oncology Reports</i> , 2018, 20, 77.	4.0	111
22	A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 519-519.	1.6	4
23	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	1.9	638
24	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. <i>European Urology</i> , 2017, 72, 354-365.	1.9	195
25	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. <i>Oncotarget</i> , 2017, 8, 34205-34222.	1.8	13
26	Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. <i>Oncotarget</i> , 2017, 8, 51675-51687.	1.8	8
27	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2017, , 1-14.		0
28	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016, 70, 611-620.	1.9	120
29	Intrinsic subtypes and bladder cancer metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 260-267.	1.2	31
30	Bladder cancer. <i>Lancet</i> , The, 2016, 388, 2796-2810.	13.7	1,031
31	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862.	1.9	228
32	New discoveries in the molecular landscape of bladder cancer. <i>F1000Research</i> , 2016, 5, 2875.	1.6	5
33	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 80164-80174.	1.8	40
34	Genetic subtypes of invasive bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 449-458.	1.8	35
35	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjöndahl, and Mattias Håglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. <i>Eur Urol</i> 2014;66:609-10. <i>European Urology</i> , 2015, 67, e76-e78.	1.9	3
36	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 377-394.	2.2	57

#	ARTICLE	IF	CITATIONS
37	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. <i>Cancer Cell</i> , 2014, 25, 152-165.	16.8	1,358
38	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 400-410.	3.8	267
39	New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. <i>European Urology</i> , 2014, 66, 609-610.	1.9	55
40	A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. <i>Cancer Biology and Therapy</i> , 2013, 14, 812-822.	3.4	18
41	The p63 Protein Isoform $\Delta Np63\alpha$ Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 3275-3288.	3.4	116
42	Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting. <i>PLoS ONE</i> , 2013, 8, e57284.	2.5	68
43	Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e69509.	2.5	35
44	p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 477-486.	3.4	18
45	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. <i>PLoS ONE</i> , 2012, 7, e30206.	2.5	71
46	Molecular Characterization of Pancreatic Cancer Cell Lines. , 2010, , 457-469.		3
47	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 429-440.	1.6	188
48	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 5820-5828.	0.9	771
49	Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines. <i>Clinical Cancer Research</i> , 2009, 15, 532-542.	7.0	76
50	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 335-344.	5.9	324
51	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5060-5072.	7.0	386
52	Inactivation of H^3N contributes to transcriptional activation of spermidine/spermine N (1)-acetyltransferase. <i>Molecular Carcinogenesis</i> , 2006, 45, 685-693.	2.7	14
53	Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. <i>Cancer Biology and Therapy</i> , 2006, 5, 1450-1456.	3.4	20
54	Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 3295-3304.	3.4	48

#	ARTICLE	IF	CITATIONS
55	Understanding Cancer through Proteomics. Technology in Cancer Research and Treatment, 2002, 1, 221-230.	1.9	0
56	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	9